Bioprocess technology for organoid production
Organoid line expansion service using unique bioprocess technology for high-throughput applications
Patent-pending bioprocess has the potential to produce tens of millions of quality-controlled organoids per batch
Quality-controlled organoids are manufactured at scale for high-throughput screening, leveraging proprietary bioreactor and patent-pending bioprocess technology to produce efficient, reproducible, scalable PDOs. Production of standardized, assay-ready organoids originating from customer-supplied organoid lines or patient-derived xenografts (PDX) can be deployed in many applications, including drug discovery and organ-on-a-chip applications.
Until recently, organoids could only be grown and expanded manually. This is a technically challenging, time-consuming, and labor-intensive process resulting in small numbers of inconsistently sized organoids, limiting their suitability for use in high throughput applications and widespread use by big pharma and biotech.
"This unique service will allow researchers to screen thousands to tens of thousands of drug candidates in parallel on organoids from the same batch, increasing statistical power and enabling the discovery of new therapeutics cost-effectively, faster, and with fewer failures,” states Shantanu Dhamija, Vice President of Strategy and Innovation. Read press release, "Molecular Devices launches custom organoid line expansion service"
This 'disruptive’ Molecular Devices bioprocess, now in its second generation, has enabled a significant increase in standardized PDO volume production compared to manual processes. Improved process control, including the use of inline sensors and real-time monitoring, ensures precise culture conditions for large, reproducible batches of standardized organoids. This is a significant step change from existing manual PDO culture methods, enabling organoids to be used in high-throughput assays earlier in the drug discovery cascade.
